The benefit of PARP inhibitors varied significantly based on the tumor's molecular profile, particularly its homologous recombination repair capability. While patients with deficiencies in this ...

Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 ...

High-risk advanced ovarian cancer patients showed marginal survival benefit with bevacizumab added to first-line chemotherapy. Patients without high-risk characteristics did not show significant ...

Ovarian cancer management is challenging due to high morbidity and mortality, often from late-stage diagnoses. Advances in tumor genomics have led to targeted therapies, improving outcomes for ...

Terri Baker was diagnosed with stage 4 ovarian cancer in September. Today, the cancer is undetectable. When Terri Baker walked into an emergency room for blood in her urine, doctors diagnosed her with ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

OVATION 3 phase 3 trial investigates IMNN-001 for advanced ovarian cancer, focusing on overall survival as the primary endpoint. The trial site at Washington University School of Medicine is the first ...

Opportunistic salpingectomy, or the removal of fallopian tubes in women already undergoing another abdominal or gynecological ...